Your browser doesn't support javascript.
loading
A cell-based assay for the detection of neutralizing antibodies against alemtuzumab.
Ali, Liaqat; Saxena, Gauri; Jones, Meleri; Leisegang, Georgia R; Gammon, Luke; Gnanapavan, Sharmilee; Giovannoni, Gavin; Schmierer, Klaus; Baker, David; Kang, Angray S.
Afiliação
  • Ali L; Barts & The London School of Medicine & Dentistry, Blizard Institute, Queen Mary University of London, Whitechapel, London, UK.
  • Saxena G; Department of Biological Sciences, National University of Medical Sciences (NUMS), Rawalpindi 46000, Pakistan.
  • Jones M; Barts & The London School of Medicine & Dentistry, Blizard Institute, Queen Mary University of London, Whitechapel, London, UK.
  • Leisegang GR; Barts & The London School of Medicine & Dentistry, Blizard Institute, Queen Mary University of London, Whitechapel, London, UK.
  • Gammon L; Centre for Oral Immunobiology & Regenerative Medicine, Institute of Dentistry, Barts & the London School of Medicine & Dentistry, Queen Mary University of London, London, E1 2AT, UK.
  • Gnanapavan S; Barts & The London School of Medicine & Dentistry, Blizard Institute, Queen Mary University of London, Whitechapel, London, UK.
  • Giovannoni G; BartsMS, Blizard Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, E1 2AT, UK.
  • Schmierer K; Clinical Board: Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, E1 1BB, UK.
  • Baker D; BartsMS, Blizard Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, E1 2AT, UK.
  • Kang AS; Clinical Board: Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, E1 1BB, UK.
Biotechniques ; 68(4): 185-190, 2020 04.
Article em En | MEDLINE | ID: mdl-32096651
ABSTRACT

Aim:

The humanized anti-CD52 monoclonal antibody alemtuzumab depletes lymphocytes and is currently used to treat relapsing multiple sclerosis. During treatment, anti-alemtuzumab antibodies may develop and reduce effective lymphocyte depletion in future treatment cycles.

Results:

Alemtuzumab-Alexa Fluor 488 conjugate binding to the CHO-CD52 cell surface was inhibited by anti-alemtuzumab antibodies.

Conclusion:

In this proof-of-concept study, a CHO-CD52 cell line has been developed and used to detect the presence of anti-alemtuzumab neutralizing antibodies. This platform provides the basis of an assay for routine screening of serum for neutralizing antibodies from patients treated with alemtuzumab.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoensaio / Técnicas Citológicas / Anticorpos Neutralizantes / Alemtuzumab Tipo de estudo: Diagnostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoensaio / Técnicas Citológicas / Anticorpos Neutralizantes / Alemtuzumab Tipo de estudo: Diagnostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article